Abcuro Stock
HealthTechLooking to sell Abcuro stock or options?
Abcuro is an innovator in immunomodulatory therapeutics, focused on developing treatments for autoimmune diseases and cancer. The company employs a unique analysis of human disease transcription data to uncover novel strategies for targeting critical components of the immune system. This approach empowers healthcare professionals to design effective treatment plans and execute efficient therapeutic procedures.
Sanofi Ventures, Redmile Group, Soleus Capital, Pontifax Venture Capital, Foresite Capital, Hongsen Investment, Samsara BioCapital, New Enterprise Associates, Mass General Brigham Ventures, Mass General Brigham Innovation, Abrdn, New Leaf Venture, BlackRock, U.S. Department of Health and Human Services, RA Capital Management, ShangBay Capital, Bain Capital Life Sciences, Eurofarma Ventures, Myeloma Investment Fund, Kaitai Capital.